A. Keith Stewart, MB, ChB: Outcomes for multiple myeloma patients have improved dramatically over the past decade. This has come about as the result of the introduction of a whole new class of novel ...

Combination therapies in multiple myeloma show superior efficacy over monotherapies, with higher response rates and progression-free survival. Monotherapy with agents like Empliciti and Darzalex shows ...

Amrita Krishnan, MD, FACP: Combination chemotherapy for myeloma has really changed the paradigm, as well as responses, in myeloma. We recognize that each myeloma patient has multiple clones of the ...

When multiple myeloma comes back after standard treatments like lenalidomide and daratumumab, patients often need new options ...

Please provide your email address to receive an email when new articles are posted on . Patients had a reduced risk for disease progression or death when treated with daratumumab-lenalidomide vs.

Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% ...